# A Phase Ib Safety lead-in, Followed by Phase II Trial of ADG106 in Combination With Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer

> **NCT05275777** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **National University Hospital, Singapore** · enrollment: 66 (estimated)

## Conditions studied

- HER2-negative Breast Cancer
- Advanced Solid Tumor

## Interventions

- **DRUG:** ADG106
- **DRUG:** Doxorubicin
- **DRUG:** Cyclophosphamide
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT05275777
- **Lead sponsor:** National University Hospital, Singapore
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-05-19
- **Primary completion:** 2027-12
- **Final completion:** 2030-02
- **Target enrollment:** 66 (ESTIMATED)
- **Last updated:** 2025-07-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05275777

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05275777, "A Phase Ib Safety lead-in, Followed by Phase II Trial of ADG106 in Combination With Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT05275777. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*